TARDBP and cancer: It can manifest as gain‐of‐function that generate oncogenic condensates, exemplified by SRSF9 or hnRNP A1 in cancer [56, 120] (Section 4.2.1), or loss‐of‐function, leading to toxic aggregation or mislocalization as seen for TDP‐43 in ALS/FTD [115] and RBM20 [113, 114].